Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PK11195 is a synthetic small molecule that acts as a selective antagonist of the translocator protein (TSPO), formerly known as the peripheral benzodiazepine receptor (PBR). It binds with high affinity to TSPO and has been widely used as a research tool and radioligand marker for imaging neuroinflammation and neuronal damage in animal models and humans. The compound is also studied for its ability to induce apoptosis in certain cancer cells (notably chronic lymphocytic leukemia) by mechanisms involving mitochondrial depolarization and cytochrome c release. In addition to its use in positron emission tomography (PET) imaging—especially when radiolabeled ([11C]PK11195)—it has been investigated preclinically for potential anticancer effects and chemosensitization of tumor cells but has not advanced beyond early-stage research[4][5][7][8][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on PK11195.